Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 7/20 | 0.64 |
| ▸ | SCN2A | Q99250 | 6/20 | 0.64 |
| ▸ | HPGDS | O60760 | 4/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | NQO2 | P16083 | 1/20 | 0.48 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.47 |
| ▸ | MASP2 | O00187 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31614566 | 0.91 | SCN2A (0.73) | NPY5RSCN2AHPGDSTRPV1 | |
| SCHEMBL6027461 | 0.84 | SCN2A (0.56) | NPY5RSCN2AHPGDS | |
| SCHEMBL6887923 | 0.84 | SCN2A (0.56) | NPY5RSCN2AHPGDSMASP2 | |
| SCHEMBL6026722 | 0.84 | SCN2A (0.58) | NPY5RSCN2A | |
| SCHEMBL17283469 | 0.81 | SCN2A (0.96) | NPY5RSCN2AHPGDSNQO2MASP2 | |
| SCHEMBL4053949 | 0.81 | MASP2 (0.70) | NPY5RSCN2ATRPV1ASIC3MASP2 | |
| SCHEMBL1180501 | 0.79 | SCN2A (0.64) | NPY5RSCN2AHPGDSTRPV1NQO2 | |
| SCHEMBL22668206 | 0.79 | SCN2A (0.86) | NPY5RSCN2AHPGDSTRPV1 | |
| Hydrochloric Acid SCHEMBL4061012 | 0.79 | MASP2 (0.68) | NPY5RSCN2ATRPV1ASIC3MASP2 | |
| SCHEMBL6027412 | 0.78 | SCN2A (0.42) | NPY5RSCN2AHPGDSTRPV1NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613310-A1 | IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS | Avanir Pharmaceuticals (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20040229927-A1 | Imidazole derivatives for treatment of allergic and hyperproliferative disorders | AVANIR PHARMACEUTICALS | 2004-11-18 | — | — | US | disclosed |
| WO-2004091610-A1 | IMIDAZOLE DERIVATIVES FOR TREATMENT OF ALLERGIC AND HYPERPROLIFERATIVE DISORDERS | AVANIR PHARMACEUTICALS (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229927-A1 | Imidazole derivatives for treatment of allergic and hyperproliferative disorders | ICOS, TSLP, IKZF3 | NPY5R 4342/4885SCN2A 4668/4885HPGDS 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.